AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05590078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality Satisfaction Score
Description: Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding virtual reality session
Study NCT05590078 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Perioperative care satisfaction score
Description: Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding perioperative care
Study NCT05590078 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perioperative care satisfaction score
Description: Likert scale satisfaction questionnaire to collect the patients' satisfaction regarding perioperative care
Study NCT05345964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GST-HG151
Description: Subjects will take GST-HG151 orally(once daily) on Day 1
Study NCT05345964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take Placebo orally(once daily) on Day 1
Study NCT05345964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GST-HG151
Description: Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7
Study NCT05345964 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take Placebo orally (once daily) from day 1 to day 7
Study NCT05345964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GST-HG151
Description: Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
Study NCT05345964 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GST-HG151
Description: Group B was administered under the postprandial conditions of Day1 in the first cycle, and under the sky-abdominal conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.
Study NCT06493968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: Uterotonics will be given in the form of an IV bolus of 10 units of oxytocin immediately with the uterine incision
Study NCT06493968 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: IV bolus of normal saline immediately with the uterine incision
Study NCT04432883 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Experimental: Active cathodal tDCS + language training
Description: Cathodal tDCS raises neuronal membrane potentials, leading to decreased probability of depolarization from incoming stimuli.~Speech and Language training involves a combined semantic feature analysis and phonological components analysis treatment.
Study NCT04432883 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Comparator: Placebo cathodal tDCS + Speech and language
Description: Speech and Language training involves a combined semantic feature analysis and phonological components analysis treatment. .
Study NCT06079450 — intervention group
Intervention type: OTHER
Intervention: artificial intelligence based mobile application
Description: Artificial intelligence-based mobile application developed by me that includes diabetes education for individuals with diabetes.
Study NCT05142527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADM03820
Description: ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies
Study NCT05142527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT04220957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Impression Technique
Description: Digital impressions of both arches will be taken by using an intraoral scanner (Trios 3, 3Shape, Denmark) by adhering to the scanning pattern recommended by the company for routine diagnosis and recording.
Study NCT04220957 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Impression Technique
Description: Conventional Impression Technique of both arches will be taken with alginate (Orthoprint, Zhermack) on conventional stainless steel impression trays.
Study NCT05773001 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ozone
Description: Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
Study NCT05015088 — intervention group
Intervention type: OTHER
Intervention: No interventions will be performed in this study
Description: This study will not include any intervention
Study NCT05949905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage-matched interventions
Description: The intervention would be using the Processes of Change that match each Stage of Change.
Study NCT05354362 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: ATG-010 and ATG-008
Description: Patients enrolled will receive consecutive daily treatment at assigned dose level. The starting dose of ATG-010 at the dose escalation phase will be 60 mg QW, which could be escalated to 80 mg QW, 100 mg QW, 60 mg BIW. In case 60 mg QW of ATG-010 with any dose of ATG-008 is NOT tolerable, 40 mg QW ATG-010 could be explored. The starting dose of ATG-008 will be 15 mg QD, which could be escalated to 20 mg QD, with maximum of 30 mg QD. SRC will be consulted before each dose escalation starts.
Study NCT06371001 — intervention group
Intervention type: OTHER
Intervention: disease
Description: Helicobacter Pylori Infection In Chonic Kidney Diseased Patien
Study NCT05997303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Continuous norepinephrine infusion via an infusion pump
Description: Patients will be randomized 1:1 to continuous norepinephrine infusion via an infusion pump or to manual bolus norepinephrine administration. The norepinephrine dose will be at the discretion of the treating anesthesiologists.
Study NCT05997303 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Manual bolus norepinephrine administration
Description: Patients will be randomized 1:1 to continuous norepinephrine infusion via an infusion pump or to manual bolus norepinephrine administration. The norepinephrine dose will be at the discretion of the treating anesthesiologists.
Study NCT04776655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: This is the treatment assigned to experimental arm:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
Study NCT04776655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: This is the treatment assigned to control arm:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
Study NCT04776655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
Study NCT04776655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
Study NCT04776655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
Study NCT04776655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
Study NCT04776655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium levofolinate
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
Study NCT05530226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine
Description: Traditional Chinese medicine, oral administration, twice daily
Study NCT04776655 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium levofolinate
Description: FOLFIRI regimen: This is the treatment assigned to control and to experimental arms:~All treatments will continue until disease progression, death, unacceptable toxicity, clinical decision or consent withdrawn.
Study NCT05843734 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Equia forte HT
Description: Restoration of anterior class III caries lesions
Study NCT05843734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Equia forte HT
Description: Restoration of anterior class III caries lesions
Study NCT05411159 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Opioid-Free Anesthesia (OFA)
Description: Opioid-free general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.), dexmedetomidine (0.5ug/kg i.v. in 15min), and ultrasound-guided T4-5 paravertebral nerve block (0.5% Ropivacaine 20ml).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v.).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC), continuous intravenous infusion of dexmedetomidine (0.5ug/kg/h), and lidocaine (1.5mg/kg/h).~Flurbiprofen (50 mg i.v.) given at the time of skin suture.
Study NCT05411159 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard general anesthesia (OA)
Description: Standard general anesthesia protocol:~After entering the operating room, patients were given dexamethasone (5mg i.v.), atropine (0.25mg i.v.), flurbiprofen (50mg i.v.).~Induction of anesthesia with lidocaine (1.5mg/kg i.v.), sufentanil (0.3-0.4ug/kg), propofol (2-3mg/kg, i.v.), rocuronium (6-8mg i.v. ).~Intraoperative anesthesia was maintained by desflurane (0.5-1MAC) and continuous intravenous infusion of remifentanil (0.1-0.2ug/kg/min).~Flurbiprofen (50 mg i.v.) given at the time of skin suture.
Study NCT04586283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal prone position
Description: Women will be asked to lie in a prone position supported by a specially designed cushion for 30 minutes.
Study NCT06495034 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: airwave compression therapy
Description: Airwave compression therapy was given to patients after breast cancer surgery to treat the ipsilateral upper limb
Study NCT06495034 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care: health education and routine functional exercise
Description: standard care: health education and routine functional exercise
Study NCT06495034 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care: health education and routine functional exercise
Description: standard care: health education and routine functional exercise
Study NCT05013762 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fast intervention
Description: This intervention is based on recent body of evidence that high-speed movements during training are effective at improving arm movements in individuals with chronic stroke.Participants will be rewarded for movements performed within a short amount of time.
Study NCT05013762 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Active Monitoring
Description: This is an observation-only group. The training received in this group will be dose equivalent to the active group.
Study NCT05173064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Machine learning-based exercise training system
Description: The video-based exercise training system will have three key features:~1. Evidence-based exercise videos instructed by physical therapists~2. Real-time movement feedback and performance score~3. Exercise records.
Study NCT05173064 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video-based exercise training system
Description: The video-based system will only include the exercise videos as those involved in the machine learning-based system. The features of real-time movement feedback and tracking of exercise progress will not be provided.
Study NCT06309134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Families Bright Futures Program
Description: Seven weekly online group sessions with separate sessions for teens and caregivers. Sessions focus on increasing knowledge and acceptance of LGBTQ+ identities, alcohol use and dating violence social norms correction, bystander intervention, assertive communication skills, social emotional skills, family problem solving, and parenting behaviors.
Study NCT06303869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS) of the Motor Thalamus
Description: All participants enrolled in this group will undergo a surgical procedure to implant deep brain stimulation electrode leads. The electrodes will be connected to external stimulators and a series of experiments will be performed to identify the types of movements that the hand and arm can make and how speech abilities are affected by the stimulation. The implant will be removed after less than 30 days.
Study NCT05159336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS for auditory hallucinations via single arm
Description: a 20 weeks, weekly 40 minutes, 1mA, 10Hz-tACS protocol
Study NCT06204835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RD-Cy7 fluorophore
Description: Fluorophore targeting ITGA6 that is overexpressed in HCC cells
Study NCT00842322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: high fluid intake
Description: fluid intake of 4 litres per day
Study NCT00842322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: normal fluid intake
Description: Fluid intake of 2 litres per day
Study NCT05606471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide Pen Injector [Ozempic]
Description: Glucagon-like peptide 1 (GLP-1) receptor agonist
Study NCT05606471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Pen Injector [Ozempic]
Description: Glucagon-like peptide 1 (GLP-1) receptor agonist
Study NCT05606471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Very-low Calorie Diet
Description: Total meal replacement with a limit of 800 kilocalories per day
Study NCT05606471 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Very-low Calorie Diet
Description: Total meal replacement with a limit of 800 kilocalories per day
Study NCT05066932 — intervention group
Intervention type: OTHER
Intervention: Additionnal blood samples
Description: Additionnal blood samples
Study NCT05209633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granules Dendrobii
Description: 6g each, 3 times per day, total 18 weeks
Study NCT05209633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT05926700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Candonilimab
Description: The patients were treated with Candonilimab + anlotinib, with Cadonilimab 10mg/kg, D1 administration; Anlotinib 12mg/ day was orally administered for 2 weeks and stopped for a week, with 21 days as a course of treatment.
Study NCT04839731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination topical 5-fluorouracil 5% / calcipotriene 0.005% cream
Description: Apply twice per day for allotted time
Study NCT04839731 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nourivan Base Cream
Description: Apply twice per day for allotted time
Study NCT04987788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motívate
Description: The Motívate app can be used in English or Spanish and involves four sequential phases. 1) The engaging phase uses videos to welcome participants. 2) Patients willing to discuss the decision to have a screening colonoscopy will answer multiple-choice questions on colorectal cancer prevention - completing the focusing phase. Optional videos will offer additional information. 3) The evoking phase consists of interactive Motivational Interviewing exercises to help participants elicit motivations to get a screening colonoscopy. 4) During the planning phase, participants will view a video that will discuss the steps needed to prepare for the colonoscopy.
Study NCT04987788 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video link
Description: General health information video link
Study NCT05285293 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Platelet Rich Fibrin (PRF)
Description: Platelet rich fibrin (PRF) in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
Study NCT06338969 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbohydrate Restriction after a Gastric Bypass
Description: All patients will undergo laparoscopic one anastomotic gastric bypass. In the postoperative period, all patients will receive normal daily amounts of protein and fat. Depending on the amount of carbohydrates that will be received after surgery, patients will randomly (no mask) be divided into three groups:~The first group: 51-75% deficit in carbohydrates Second group: 26-50% deficit in carbohydrates The third group: has a 1-25% deficit in carbohydrates.
Study NCT05285293 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Fibrin (PRF) and Retinol
Description: Platelet rich fibrin (PRF) mixed with Retinol in treatment of intrabony defects using Modified Minimally invasive surgical technique (M-MIST)
Study NCT06338969 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate Restriction after a Gastric Bypass
Description: All patients will undergo laparoscopic one anastomotic gastric bypass. In the postoperative period, all patients will receive normal daily amounts of protein and fat. Depending on the amount of carbohydrates that will be received after surgery, patients will randomly (no mask) be divided into three groups:~The first group: 51-75% deficit in carbohydrates Second group: 26-50% deficit in carbohydrates The third group: has a 1-25% deficit in carbohydrates.
Study NCT05270070 — intervention group
Intervention type: OTHER
Intervention: Appointment booking system
Description: Patients were sent an email to book an appointment using the telephone/email versus a online booking system.
Study NCT05634967 — intervention group
Intervention type: OTHER
Intervention: Kesimpta
Description: Prospective non-interventional study. There is no treatment allocation. Patients participating in from the two independent sub-studies, namely the Kesimpta-OTIS sub-study and Kesimpta-DMSKW sub-study, of identical design, conducted in parallel, enrolling pregnant women (MS and non-MS) residing in US or Canada and pregnant women (MS only) from Germany respectively are eligible for enrolling to this study.
Study NCT05845424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Guideline directed statin therapy
Description: At least moderate intensity statin, recommended by the current guideline based on the ASCVD risk
Study NCT05341960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Food Delivery
Description: Food box with food to feed a family of four, delivered by the Greater Cleveland Food Bank every two weeks. Based on participant preferences, includes recipes.
Study NCT05341960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Support
Description: Provides supplemental funds to purchase healthy foods; provides choice. Includes recipes for limited budgets and assistance locating healthy food options in their specific neighborhood.
Study NCT05680688 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy
Description: * Postero-anterior mobilizations: the physiotherapist will place his thumbs on the posterior surface of the spinous process of the vertebra previously assessed as the most painful to mobilise. The oscillations will be performed at the frequency of 1 oscillation per second and will be performed 3 series of 3 minutes, with a 1 minute rest interval.~* Pressure: The point of greatest pain shall be treated by maintained pressure in each of the following areas: right upper trapezius, left upper trapezius, right paravertebral musculature and left paravertebral musculature. Pressure shall be applied to each of the points for 1 minute.~* Massage: Pressure is applied to the muscles by sliding along the muscle belly. This will be done slowly to control the pain that is being provoked. 3 minutes will be carried out on each upper trapezius, sliding from the acromion to the occipital and another 3 minutes on the paravertebral musculature on each side, sliding from T1 to the occipital.